Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.
Hau, P MD; Koch, D MD; Hundsberger, T MD; Marg, E MD; Bauer, B MD; Rudolph, R MD; Rauch, M MD; Brenner, A MD; Rieckmann, P MD; Schuth, J MD; Jauch, T RN; Koch, H MD, PhD; Bogdahn, U MD
68(9):688-690, February 27, 2007.
(Format: HTML, PDF)
mdash;: We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.
(C) 2007 American Academy of Neurology